AMN006 - Phase 2 Study of Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

06 Jul 2023 Status changed from recruiting to active, no longer recruiting.
06 May 2020 Planned End Date changed from 1 Oct 2023 to 1 Apr 2024.
06 May 2020 Planned primary completion date changed from 1 Mar 2021 to 1 Sep 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com